Diagnosis and Treatment of Peripheral Arterial Disease Compared with Other Atherosclerotic Vascular Diseases in a University Primary Care Clinic

2006 ◽  
Vol 54 (5) ◽  
pp. 255-261 ◽  
Author(s):  
Hassan M. Ismail ◽  
Kyoo Jackson ◽  
Daniel Smith
Keyword(s):  
Primary Care ◽  
Peripheral Arterial Disease ◽  
Primary Care Clinic ◽  
Vascular Diseases ◽  
Arterial Disease ◽  
Diagnosis And Treatment ◽  
Care Clinic ◽  
Peripheral Arterial

scholarly journals Platelet aggregation inhibitor prescription for newly diagnosed peripheral arterial disease in the Netherlands: a cohort study

BMJ Open ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. e041715
Author(s):  
Aarent RT Brand ◽  
Eline Houben ◽  
Irene D Bezemer ◽  
Frank L J Visseren ◽  
Michiel L Bots ◽  
...  
Keyword(s):  
Primary Care ◽  
Cohort Study ◽  
The Netherlands ◽  
Peripheral Arterial Disease ◽  
Arterial Disease ◽  
Free Text ◽  
Newly Diagnosed ◽  
Patient Journey ◽  
P2y12 Inhibitors ◽  
Peripheral Arterial

ObjectivesPharmacological treatment of peripheral arterial disease (PAD) comprises of antiplatelet therapy (APT), blood pressure control and cholesterol optimisation. Guidelines provide class-I recommendations on the prescription, but there are little data on the actual prescription practices. Our study provides insight into the prescription of medication among patients with PAD in the Netherlands and reports a ‘real-world’ patient journey through primary and secondary care.DesignWe conducted a cohort study among patients newly diagnosed with PAD between 2010 and 2014.SettingData were obtained from the PHARMO Database Network, a population-based network of electronic pharmacy, primary and secondary healthcare setting records in the Netherlands. The source population for this study comprised almost 1 million individuals.Participants‘Newly diagnosed’ was defined as a recorded International Classification of Primary Care code for PAD, a PAD-specific WCIA examination code or a diagnosis recorded as free text episode in the general practitioner records with no previous PAD diagnosis record and no prescription of P2Y12 inhibitors or aspirin the preceding year. The patient journey was defined by at least 1 year of database history and follow-up relative to the index date.ResultsBetween 2010 and 2014, we identified 3677 newly diagnosed patients with PAD. Most patients (91%) were diagnosed in primary care. Almost half of all patients (49%) had no APT dispensing record. Within this group, 33% received other anticoagulant therapy (vitamin K antagonist or direct oral anticoagulant). Mono-APT was dispensed as aspirin (40% of patients) or P2Y12 inhibitors (2.5% of patients). Dual APT combining aspirin with a P2Y12 inhibitor was dispensed to 8.5% of the study population.ConclusionHalf of all patients with newly diagnosed PAD are not treated conforming to (international) guideline recommendations on thromboembolism prevention through APT. At least 33% of all patients with newly diagnosed PAD do not receive any antithrombotic therapy. Evaluation and improvement of APT prescription and thereby improved prevention of (secondary) cardiovascular events is warranted.

scholarly journals Nanomaterial-Mediated Theranostics for Vascular Diseases

2020 ◽  
Vol 2 (1) ◽  
pp. 1-15
Author(s):  
Swati Agrawal ◽  
Sunil K. Nooti ◽  
Harbinder Singh ◽  
Vikrant Rai
Keyword(s):  
Peripheral Arterial Disease ◽  
Therapeutic Agent ◽  
Molecular Level ◽  
Vascular Diseases ◽  
Arterial Disease ◽  
Imaging Studies ◽  
Leg Muscles ◽  
Diagnostic Agents ◽  
Peripheral Arterial ◽  
Complementary Strategy

Nanotechnology could offer a new complementary strategy for the treatment of vascular diseases including coronary, carotid, or peripheral arterial disease due to narrowing or blockage of the artery caused by atherosclerosis. These arterial diseases manifest correspondingly as angina and myocardial infarction, stroke, and intermittent claudication of leg muscles during exercise. The pathogenesis of atherosclerosis involves biological events at the cellular and molecular level, thus targeting these using nanomaterials precisely and effectively could result in a better outcome. Nanotechnology can mitigate the pathological events by enhancing the therapeutic efficacy of the therapeutic agent by delivering it at the point of a lesion in a controlled and efficacious manner. Further, combining therapeutics with imaging will enhance the theranostic ability in atherosclerosis. Additionally, nanoparticles can provide a range of delivery systems for genes, proteins, cells, and drugs, which individually or in combination can address various problems within the arteries. Imaging studies combined with nanoparticles helps in evaluating the disease progression as well as the response to the treatment because imaging and diagnostic agents can be delivered precisely to the targeted destinations via nanocarriers. This review focuses on the use of nanotechnology in theranostics of coronary artery and peripheral arterial disease.

scholarly journals Detecting Peripheral Arterial Disease in Primary Care: A Population Based Study

2020 ◽  
Vol 41 (1) ◽  
pp. 61-67
Author(s):  
Tolga Vural ◽  
Makbule Neslişah Tan ◽  
Mehtap Kartal ◽  
Azize Dilek Güldal
Keyword(s):  
Primary Care ◽  
Peripheral Arterial Disease ◽  
Arterial Disease ◽  
Population Based ◽  
Population Based Study ◽  
Peripheral Arterial

scholarly journals Prevalence and predictors of peripheral arterial disease determined by ankle brachial index in diabetes population treated within primary care services in a non-urban area of lower northern Thailand

2020 ◽  
Vol 17 (6) ◽  
pp. 147916412096699
Author(s):  
Preaw Suwannasrisuk ◽  
Sarinya Sattanon ◽  
Watcharaporn Taburee ◽  
Pantitra Singkheaw ◽  
Non Sowanna ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Primary Care ◽  
Peripheral Arterial Disease ◽  
Ankle Brachial Index ◽  
Arterial Disease ◽  
University Hospital ◽  
Peripheral Arterial ◽  
Diabetes Patients

In diabetes patients, urban lifestyle has been concerned as one of the risk factors for peripheral arterial disease (PAD). The aims of this study were to find out the prevalence and associated risk factors of PAD in type 2 diabetes patients who live in a non-urban community area. A total of 885 participants with type 2 diabetes mellitus were enrolled from six primary care units in the health network centered at Naresuan University Hospital, Phitsanulok, between May and June 2018. Ankle-brachial index (ABI) was performed in all subjects using a vascular screening device. PAD was defined by an ABI value of 0.9 or lesser at least on one leg. The predictors of PAD were analyzed using multiple logistic regression. The prevalence of PAD was 7.2% among 884 evaluable patients. Diabetic neuropathy and a history of macrovascular complications were significant predictors of PAD.

Sign in / Sign up

Export Citation Format

Share Document